The U.S. Food and Drug Administration approved LEQEMBI IQLIK, a weekly subcutaneous autoinjector form of lecanemab-irmb for maintenance treatment of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE